0000310158FALSE00003101582026-10-092026-10-090000310158us-gaap:CommonStockMember2026-10-092026-10-090000310158mrk:A3.250NotesDue2032Member2026-10-092026-10-090000310158mrk:A2.500Notesdue2034Member2026-10-092026-10-090000310158mrk:A1.375Notesdue2036Member2026-10-092026-10-090000310158mrk:A3.500NotesDue2037Member2026-10-092026-10-090000310158mrk:A3.700NotesDue2044Member2026-10-092026-10-090000310158mrk:A3.750NotesDue2054Member2026-10-092026-10-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 18, 2026 (November 16, 2026)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
New Jersey | 1-6571 | 22-1918501 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S Employer Identification No.) |
| | | | | | | | |
126 East Lincoln Avenue |
Rahway | New Jersey | 07065 |
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code) (908) 740-4000
Not applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock ($0.50 par value) | MRK | New York Stock Exchange |
| 3.250% Notes due 2032 | MRK/32 | New York Stock Exchange |
| 2.500% Notes due 2034 | MRK/34 | New York Stock Exchange |
| 1.375% Notes due 2036 | MRK 36A | New York Stock Exchange |
| 3.500% Notes due 2037 | MRK/37 | New York Stock Exchange |
| 3.700% Notes due 2044 | MRK/44 | New York Stock Exchange |
| 3.750% Notes due 2054 | MRK/54 | New York Stock Exchange |
| | | | | | | | |
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging growth company ☐ | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On November 16, 2026, Thomas H. Glocer gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2027 Annual Meeting of Shareholders. Mr. Glocer’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued November 18, 2026
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| Merck & Co., Inc. |
| | |
Date: November 18, 2026 | | By: | /s/ Kelly E. W. Grez |
| | | Kelly E. W. Grez |
| | | Corporate Secretary |
News Release____________________________________________________________________________
FOR IMMEDIATE RELEASE
Thomas H. Glocer to Retire from Merck Board of Directors in May 2027;
Douglas M. Baker, Jr. Appointed Independent Lead Director
RAHWAY, N.J., Nov. 18, 2026 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Thomas H. Glocer intends to retire from the Merck Board of Directors at the Company’s Annual Meeting of Shareholders in May 2027. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role.
Mr. Baker has served on the Merck Board of Directors since 2022. He has wide-ranging expertise in corporate governance and organizational management, including a deep understanding of global marketing, sales and operations of public companies. Previously, Mr. Baker was chairman and chief executive officer of Ecolab Inc., a provider of water and hygiene services and technologies for the food, hospitality, industrial and energy markets. He is also a trustee of Mayo Clinic.
“Merck has counted on Tom’s expertise and counsel as a trusted voice in our boardroom for many years, and I have relied on him as a valued collaborator. His contributions to our Company have been invaluable, and on behalf of everyone at Merck, I thank him for his dedicated service,” said Rob Davis, chairman and chief executive officer, Merck. “As we look ahead, Doug is a thoughtful, experienced and accomplished leader who will undoubtedly serve the Board well in this expanded role. I look forward to our continued work together as we deliver value to our stakeholders.”
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on
X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
###
| | | | | |
Media Contacts: | Investor Contacts: |
Michael Levey michael.levey@merck.com
John Cummins john.cummins2@merck.com |
Peter Dannenbaum (732) 594-1579
Steven Graziano (732) 594-1583 |